The identification of KRASG12C inhibitors has reignited interest in targeting RAS proteins. This work describes the discovery of the KRASG12D-specific inhibitor MRTX1133 and demonstrates the feasibility of potently and selectively targeting this oncogenic variant. MRTX1133 treatment markedly inhibited KRAS-dependent signaling and induced tumor regression in xenograft models harboring the KRASG12D mutation.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Innovative drugs promote precision cancer therapy
Clinical Cancer Bulletin Open Access 06 December 2023
-
RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment
Journal of Translational Medicine Open Access 05 September 2023
-
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Signal Transduction and Targeted Therapy Open Access 23 May 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Bos, J. L. Ras oncogenes in human cancer: a review. Cancer Res. 49, 4682–4689 (1989). A review article that provides an overview of RAS family gene mutations and links to oncogenesis.
Fernandez-Medarde, A. & Santos, E. Ras in cancer and development diseases. Genes Cancer 2, 344–358 (2011). A review article that summarizes the contributions of RAS mutations and altered RAS signaling to carcinogenesis.
Ostrem, J. M. & Shokat, K. M. K-RasG12C inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551 (2013). A report that describes the structure-based validation of an allosteric regulatory site on KRASG12C that was found to be selectively targetable.
Wang, X. & Marx, M. A. Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor. J. Med. Chem. 65, 3123–3133 (2022). The structure-based discovery and characterization of MRTX1133.
Hallin, J. & Christensen, J. G. The KRASG12C inhibitor, MRTX849, provides insight toward therapeutic susceptibility of KRAS mutant cancers in mouse models and patients. Cancer Discov. 10, 54–71 (2020). The functional evaluation and characterization of MRTX849, including patient data, illustration of resistance mechanisms, and identification of potentially effective treatment combinations.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Hallin, J. et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat. Med. https://doi.org/10.1038/s41591-022-02007-7 (2022).
Rights and permissions
About this article
Cite this article
The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis. Nat Med 28, 2017–2018 (2022). https://doi.org/10.1038/s41591-022-02008-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-02008-6
This article is cited by
-
RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment
Journal of Translational Medicine (2023)
-
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Signal Transduction and Targeted Therapy (2023)
-
Innovative drugs promote precision cancer therapy
Clinical Cancer Bulletin (2023)